Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies
Yoshihito Kano · 2026
Read Precision Targeting of KRAS-Mutant Cancers: Beyond G12C Toward G12D and Pan-RAS Therapeutic Strategies by Yoshihito Kano (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13362513.txt.
Description
Yoshihito Kano wrote a 2026 review on drugs that target KRAS, one of the most common cancer-driving genes. KRAS faults drive many lung, bowel, and pancreas cancers, and for decades the protein was seen as impossible to drug. The review covers the first approved blockers, aimed at one fault type, and the push toward drugs for other types and for KRAS as a whole.
Newer plans include drugs for the G12D fault, broad RAS blockers, and protein degraders, often paired in combinations guided by blood tests for tumor DNA. Resistance still cuts responses short, so tracking how tumors adapt is a core theme. Kano maps where this fast field stands and what must come next.
Catalog record
| CREATOR | Yoshihito Kano |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 50303 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |